Browse TDRD5

Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cytoplasm Note=Localizes to chromatoid body (CB) and pi-body (also called intermitochondrial cementin), 2 cytoplasmic ribonucleoprotein granules involved in RNA processing for spermatogenesis.
Domain PF12872 OST-HTH/LOTUS domain
PF00567 Tudor domain
Function

Required during spermiogenesis to participate in the repression transposable elements and prevent their mobilization, which is essential for the germline integrity. Probably acts via the piRNA metabolic process, which mediates the repression of transposable elements during meiosis by forming complexes composed of piRNAs and Piwi proteins and govern the methylation and subsequent repression of transposons. Required for chromatoid body (CB) assembly (By similarity).

> Gene Ontology
 
Biological Process GO:0000578 embryonic axis specification
GO:0003002 regionalization
GO:0006304 DNA modification
GO:0006305 DNA alkylation
GO:0006306 DNA methylation
GO:0007028 cytoplasm organization
GO:0007281 germ cell development
GO:0007283 spermatogenesis
GO:0007286 spermatid development
GO:0007292 female gamete generation
GO:0007308 oocyte construction
GO:0007309 oocyte axis specification
GO:0007314 oocyte anterior/posterior axis specification
GO:0007315 pole plasm assembly
GO:0007350 blastoderm segmentation
GO:0007351 tripartite regional subdivision
GO:0007389 pattern specification process
GO:0008358 maternal determination of anterior/posterior axis, embryo
GO:0008595 anterior/posterior axis specification, embryo
GO:0009798 axis specification
GO:0009880 embryonic pattern specification
GO:0009948 anterior/posterior axis specification
GO:0009952 anterior/posterior pattern specification
GO:0009994 oocyte differentiation
GO:0021700 developmental maturation
GO:0022412 cellular process involved in reproduction in multicellular organism
GO:0030719 P granule organization
GO:0032259 methylation
GO:0035282 segmentation
GO:0043046 DNA methylation involved in gamete generation
GO:0043414 macromolecule methylation
GO:0044728 DNA methylation or demethylation
GO:0048232 male gamete generation
GO:0048469 cell maturation
GO:0048477 oogenesis
GO:0048515 spermatid differentiation
GO:0048599 oocyte development
GO:0071826 ribonucleoprotein complex subunit organization
Molecular Function -
Cellular Component GO:0033391 chromatoid body
GO:0035770 ribonucleoprotein granule
GO:0036464 cytoplasmic ribonucleoprotein granule
GO:0043186 P granule
GO:0045495 pole plasm
GO:0060293 germ plasm
GO:0071546 pi-body
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between TDRD5 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of TDRD5 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of TDRD5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)141201
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)6501
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)8701
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9160.1260.8
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590.0840.948
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.1860.914
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.4160.626
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15111.1980.433
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 1112-1.9640.298
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.470.487
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.9910.275
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 682300.8080.0267
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of TDRD5 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 141714.3014.30.196
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103200201
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277314.88.26.60.452
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275914.810.24.60.718
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211723.817.66.20.709
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8612.5012.51
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131130.827.33.51
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91606.2-6.21
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 590001
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 382713.27.45.80.69
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.67.75.91
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161412.57.15.41
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of TDRD5. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of TDRD5. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by TDRD5.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of TDRD5. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of TDRD5 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between TDRD5 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolTDRD5
Nametudor domain containing 5
Aliases FLJ34823; TUDOR3; Tudor domain-containing protein 5
Chromosomal Location1q24.2
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting TDRD5 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.